Bioventix PLC
LSE:BVXP

Watchlist Manager
Bioventix PLC Logo
Bioventix PLC
LSE:BVXP
Watchlist
Price: 3 750 GBX 1.08% Market Closed
Market Cap: 195.7m GBX
Have any thoughts about
Bioventix PLC?
Write Note

Bioventix PLC
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Bioventix PLC
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Bioventix PLC
LSE:BVXP
Additional Paid In Capital
ÂŁ1.5m
CAGR 3-Years
3%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Additional Paid In Capital
$987.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Additional Paid In Capital
$1B
CAGR 3-Years
20%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Additional Paid In Capital
$1.5B
CAGR 3-Years
58%
CAGR 5-Years
50%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Additional Paid In Capital
ÂŁ1.1B
CAGR 3-Years
N/A
CAGR 5-Years
39%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Additional Paid In Capital
ÂŁ179.1m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
5%
No Stocks Found

Bioventix PLC
Glance View

Market Cap
195.7m GBX
Industry
Biotechnology

Bioventix Plc engages in the development and supply of antibodies. The company is headquartered in Farnham, Surrey and currently employs 17 full-time employees. The company went IPO on 2014-04-29. The principal activity of the Company is the development and supply of antibodies. The firm specializes in the development of sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics, such as in automated immunoassays used in blood testing. The firm offers a portfolio of antibodies to customers for both commercial use and research and development (R&D) purposes, for the diagnosis or monitoring of a range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. The firm also supplies antibody products and services to multinational clinical diagnostics companies. The firm sells its products through direct sales and through distributors.

BVXP Intrinsic Value
3 076.09 GBX
Overvaluation 18%
Intrinsic Value
Price

See Also

What is Bioventix PLC's Additional Paid In Capital?
Additional Paid In Capital
1.5m GBP

Based on the financial report for Dec 31, 2023, Bioventix PLC's Additional Paid In Capital amounts to 1.5m GBP.

What is Bioventix PLC's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
29%

Over the last year, the Additional Paid In Capital growth was 10%. The average annual Additional Paid In Capital growth rates for Bioventix PLC have been 3% over the past three years , 29% over the past five years .

Back to Top